Evidence map›Paper›PMID 34503115›Full record

ArticleCancers2021

The Microenvironment of Small Intestinal Neuroendocrine Tumours Contains Lymphocytes Capable of Recognition and Activation after Expansion.

Tobias Hofving, Frank Liang, Joakim Karlsson, Ulf Yrlid, Jonas A Nilsson, Ola Nilsson, Lisa M Nilsson

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Multifaceted modeling of small intestinal neuroendocrine tumors.Endocrine oncology (Bristol, England) · 2024
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Tobias HofvingSahlgrenska Center for Cancer Research, Department of Pathology and Genetics, Institute of Biomedicine, University of Gothenburg, 40530 Gothenburg, Sweden.ORCID 0000-0002-9855-4268
Frank LiangDepartment of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, 40530 Gothenburg, Sweden.ORCID 0000-0003-3675-3816
Joakim KarlssonSahlgrenska Translational Melanoma Group, Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, University of Gothenburg, 40530 Gothenburg, Sweden.ORCID 0000-0001-6332-4043
Ulf YrlidDepartment of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, 40530 Gothenburg, Sweden.ORCID 0000-0002-3431-6770
Jonas A NilssonSahlgrenska Translational Melanoma Group, Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, University of Gothenburg, 40530 Gothenburg, Sweden.ORCID 0000-0003-0346-6837
Ola NilssonSahlgrenska Center for Cancer Research, Department of Pathology and Genetics, Institute of Biomedicine, University of Gothenburg, 40530 Gothenburg, Sweden.
Lisa M NilssonSahlgrenska Translational Melanoma Group, Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, University of Gothenburg, 40530 Gothenburg, Sweden.
University of Gothenburg · SEThe University of Western Australia · AU

Funding

Biocare strategic grantsCancerfonden project grantSahlgrenska Universitetssjukhuset ALF-grantSahlgrenska University Hospitals Research Foundations project grantSjöbergstiftelsen project grantStiftelsen Assar Gabrielssons Fond project grantSvenska Sällskapet för Medicinsk Forskning postdoc grant
6 · The paper itself

Abstract

Traditionally, immune evasion and immunotherapy have been studied in cancers with a high mutational load such as melanoma or lung cancer. In contrast, small intestinal neuroendocrine tumours (SINETs) present a low frequency of somatic mutations and are described as genetically stable tumours, rendering immunotherapies largely unchartered waters for SINET patients. SINETs frequently metastasise to the regional lymph nodes and liver at the time of diagnosis, and no curative treatments are currently available for patients with disseminated disease. Here, we characterised the immune landscape of SINET and demonstrated that tumour-infiltrating lymphocytes (TILs) can be expanded and activated during autologous tumour challenge. The composition of lymphocyte subsets was determined by immunophenotyping of the SINET microenvironment in one hepatic and six lymph node metastases. TILs from these metastases were successfully grown out, enabling immunophenotyping and assessment of PD-1 expression. Expansion of the TILs and exposure to autologous tumour cells in vitro resulted in increased T lymphocyte degranulation. This study provides insights into the largely unknown SINET immune landscape and reveals the anti-tumour reactivity of TILs, which might merit adoptive T cell transfer as a feasible treatment option for patients with SINET.

Indexed as

neuroendocrine tumourspatient-derived xenograftssmall-intestinal neuroencocrine tumorstumour-infiltrating lymphocytes

Identifiers

PMID34503115
PMCPMC8431118
OpenAlexW3194337161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.